In two sibling patients with lysinuric protein intolerance (LPI), the therapeutic effect of oral supplement of arginine and citrulline on postprandial hyperammonemia was investigated. Intravenous load of L-alanine (6.6 mmol/kg of body weight), and oral load of L-arginine (0.8 mmol/kg of body weight) or of L-citrulline (1.0 mmol/ kg of body weight) during intravenous load of L-alanine were performed to study the preventive effect of arginine or citrulline supplement on hyperammonemia induced by intravenous amino nitrogen load. In the older sibling, the hyperammonemia induced by the intravenous amino nitrogen load was completely prevented by the oral supplement of citrulline, but not completely prevented in the younger sibling. On the other hand, the hyperammonemia was prevented by the oral supplement of arginine only in the younger sibling, but not in the older sibling. In the light of these results, the younger patient received an oral administration of L-arginine and the older patient L-citrulline for the treatment of postprandial hyperammonemia. Two-year observation of each patient revealed that postpradial hyperammonemia and aversion to protein-rich food completely disappeared and that a marked increase of body weight and height was obtained. Furthermore, there was no side effect with these amino acids supplements. The present study suggests that an oral supplement of arginine or citrulline is effective for preventing postprandial hyperammonemia in this disorder.
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plasma urea associated with periodic hyperammonemia after protein-rich food ingestion are the characteristic clinical findings. Patients with this disorder have a low plasma concentration and increased urinary excretion of the dibasic amino acids, lysine, arginine and ornithine, as a result of the transport defect. Postprandial hyperammonemia is due to a lack of the urea cycle substrates, arginine and ornithine.
Since the first description of this disorder in 1965 (Perheentupa and Visakorpi), patients with LPI have been treated with low-protein diet and supplement of lysine, arginine, ornithine, or citrulline (Awrich et al. 1975 ; Russell et al. 1977 ; Rajantie et al. 1979 Rajantie et al. , 1980c . The supplement of these amino acids can prevent postprandial hyperammonemia and aversion to protein-rich food, and promote growth development in some patients.
In the present report, the therapeutic effect of oral supplement of arginine or citrulline to prevent hyperammonemia and foster growth was studied in two siblings with LPI.
MATERIALS AND METHODS
Two brothers of 14 and 7 years of age, who have been reported in another paper (Kato et al. in preparation) , had a characteristic trait of lysinuric protein intolerance (LPI). The older sibling (Case 1), one of the four children of Japanese nonconsanguineous parents, complained of nausea and vomiting after protein-rich food ingestion from 3 years of age, but had no history of diarrhea. At 14 years of age, he showed a stupor attack, and his blood ammonia level at the time was more than 500,ug/100 ml. He had a small constitution, and his body weight and height were more than 2 s.D. below the respective mean of normal subjects. Mental development was normal, and neurological examination revealed no abnormalities. The liver and spleen were palpable, 3 and 2 cm, respectively, below the costal margin, and leukocytopenia, thrombocytopenia, and elevated serum LDH activity were present (Table 1) . The EEG showed a paroxysmal spike and wave dysrhythmia. There were no other abnormal labolatory findings. The younger sibling (Case 2) also had an aversion to protein-rich food but no history of diarrhea or vomiting. His growth was also delayed. His body weight and height were more than 1.5 s.D. below the respective mean of normal subjects, but mental development was normal. Both the liver and spleen were palpable 5 cm below the costal margin. The blood ammonia level after eating was over 400,ug/100 ml, and neutrocytopenia, thrombocytopenia, and elevated serum LDH activity were also present ( Table 1 ). The other labolatory findings were normal.
There were reduced plasma levels and increased urinary excretion of the dibasic amino acids in both patients (Tables 2 and 3 ). Their parents and two sisters were healthy and had neither abnormal plasma concentration nor increased urinary excretion of the dibasic amino acids.
Control subjects were healthy children, aging 7 to 12 years. Informed consent was obtained from their parents after the nature of the study was fully explained.
In the two patients with LPI and in five control subjects, following loading tests were performed to study the preventive effect of arginine or citrulline supplement against hyperammonemia induced by intravenous amino nitrogen load : 1) intravenous load of Lalanine (6.6 mmol/kg of body weight), 2) oral load (0.8 mmol/kg of body weight) or intravenous load (0.6 mmol/kg of body weight) of L-arginine plus intravenous load of Lalanine (6.6 mmol/kg of body weight), and 3) oral load of L-citrulline (1.0 mmol/kg of body weight) plu of body weight), 2) oral load (0.8 mmol/kg of body weight) or intravenous load (0.6 mmol/kg of body weight) of L-arginine plunight fast. L-Alanine and Larginine were infused into the peripheral vein within 90 min. L-Arginine and L-citrulline Urinary excretion of dibasic amino acids and cystine and normal controls in two patients were administered orally as a 5° solusion using a naso-gastric tube simultaneously with 90 min intravenous infusion of L-alanine.
For all tests, blood samples were collected from the peripheral vein at 0, 2, 3, and 4 hr after the load. Amino acids in plasma and urine were analyzed by a Hitachi automatic amino acid analyzer (Spackman et al. 1958 ). Plasma urea was determined by the method of Bretaudiere et al. (1976) , and blood ammonia level was measured using a commercial kit based on the ion-exchange techique (Forman 1964) . 100 ml in the older patient and 387 ,u g/100 ml in the younger one (Fig. 1) . Inadequate formation of plasma urea was also observed in both patients (Fig. 2) .
In the younger sibling, hyperammonemia induced by the intravenous load of L-alanine was prevented by the oral administration of L-arginine with an adequate formation of plasma urea, but this was not found in the older sibling (Figs.  3 and 4) . Hyperammonemia induced by the intravenous load of L-alanine was prevented by the oral administration of L-citrulline in both patients, but this effect was incomplete in the younger one (Fig. 3) . Furthermore, the formation of plasma urea improved by the oral administration of L-citrulline in both patients (Fig. 4) .
In the light of these results, the two patients were put on a regimen of longterm ingestion of L-arginine or L-citrulline for the treatment of postprandial hyperammonemia.
The older patient was treated with an oral supplement of 8.0 g of L-citrulline per day, and the younger one with 5.0 g of L-arginine per day (Figs. 5 and 6), where protein intake was not restricted. Two-year observation revealed that postprandial hyperammonemia and aversion to protein-rich food had completely disappeared, and a marked increase of body weight and height was noted in both patients (Fig. 7 ). There were no side effects such as diarrhea or vomiting with the supplement of each amino acid. However, there was no lessening of hepatosplenomegaly, increased serum LDH activity, leukocytopenia or thrombocytopenia.
DISCUSSION
Lysinuric protein intolerance (LPI) is an autosomal recessive disorder characterized by a defective transport of the dibasic amino acids in the basolateral membranes of both the intestinal mucosa (Kekomaki 1968 Rajantie et al. 1981 ). In LPI, hyperammonemia is thought to be due to a lack of the urea cycle substrates arginine and ornithine ). Failure to thrive, growth and mental retardation, hepatosplenomegaly, hypotonia, vomiting and diarrhea, and aversion to protein-rich food are present in affected patients. These peculiar clinical symptoms probably derives from ammonia intoxication and intestinal malabsorption of the dibasic amino acids ). Thus, the treatment of affected patients should be based on the prevention of postprandial hyperammonemia, which if recurrent and prolonged, may lead to mental and physical retardation or even to death ). To date, arginine has been given orally to remedy the deficiency of the urea cycle intermediates (Awrich et al. 1975 ). However, some authors have reported that long-term ingestion of arginine is unsatisfactory because patients ingesting a large amount of arginine tend to have diarrhea or vomiting ). Poor intestinal absorption of arginine in patients with LPI may preclude its oral use ; Raj antie et al. 1980 a and b).
On the other hand, citrulline, a neutral intermediate of the urea cycle, is absorbed via a different mechanism from arginine, and its intestinal absorption remains intact in patients with LPI (Rajantie et al. 1980 a). Since citrulline is metabolized to arginine and ornithine in the liver, an administration of this amino acid may eliminate the deficiency of arginine and ornithine. Thus, postprandial hyperammonemia may be prevented. However, the normalization of plasma amino acids concentration is generally only temporary, because urinary loss of these amino acids increases as plasma amino acid concentration rises.
The present study showed that the preventing effect of arginine on hyperammonemia induced by intravenous amino nitrogen load in the present two siblings with LPI was different. In the younger patient, hyperammonemia induced by intravenous L-alanine load was abolished by the oral supplement of L-arginine, but this was not found in the older patient (Fig. 3) , although the intestinal transport defect of arginine in the two patients was almost the same, which was recognized by an oral arginine load test (Kato et al. in preparation) .
Generally, siblings should have the same responses to the load. However, the two brothers under study showed different responses to the arginine load in terms of prevention of postprandial hyperammonemia.
The reason remains unclear, but there may have been variations in the transport defect of arginine between the two patients. Probably the block of the intestinal absorption of arginine was incomplete in the younger patient, and it was likely that arginine, when administered in large doses, could have been partially absorbed.
Since hyperammonemia induced by the intravenous amino nitrogen load was prevented by adding an intravenous L-arginine load (Fig. 3) , it was considered that arginine transport into the hepatocytes is intact, and these results suggest that a small change in plasma arginine concentration easily affects the ammonia metabolism in the hepatocytes of LPI patients, and that if patients with LPI had a little more amount of arginine or ornithine in the blood, they would be spared ammonia intoxication. To date, the two patients have been treated with the oral supplement of arginine or citrulline, respectively, and postprandial hyperammonemia and aversion to protein-rich food have completely disappeared. Body weight and height have caught up remarkably in both patients. The supplement of arginine and citrulline produced neither diarrhea nor vomiting.
Although arginine and citrulline can prevent postprandial hyperammonemia, promote growth, and improve the protein nutrition, they cannot provide a radical cure for LPI. There is a report that hepatosplenomegaly, muscular weakness, osteoporosis, and some other biochemical abnormalties are due to a deficiency of lysine, an essential amino acid for human growth (Jansen 1962) . While lysine was not administered in this study, it is clear that arginine or citrulline can effectively prevent hyperammonemia and encourage the protein nutrition in LPI.
In conclusion, the present study suggests that, in addition to citrulline, arginine is also useful for the treatment of LPI patients, although the intestinal absorption of arginine is defective in this disorder.
